Reuters
U.S. doctors reconsider Pfizer’s Paxlovid for lower-risk COVID patients
Use of Pfizer Inc’s COVID-19 antiviral Paxlovid spiked this week, but some doctors are reconsidering the pills for lower-risk patients after a U.S. public health agency warned that symptoms can recur after people complete a course of the drug, and that they should then isolate a second time. More quarantine time “is not a crowd-pleaser,” Dr. Sandra Kemmerly, an infectious disease specialist at Ochsner Health in New Orleans, told Reuters. Use of Pfizer’s Paxlovid, authorized to treat newly infected, at-risk people in order to prevent severe illness, has soared as infections have risen.
Source: finance.yahoo.com
Related posts:
Suze Orman says you can avoid 5 common mistakes people make in a stock market crisis
A timeless bear market rule explains why dip buyers can't get a break: Morning Brief
S&P 500 would be in an ‘earnings recession’ if not for this one booming sector — but that may no...
This AI Stock Beat Nvidia Last Year, and It's Doing It Again in 2024. Is It a Screaming Buy?
Want to Leave Assets to Heirs? IRS Rule Change Should Have You Rethinking Your Irrevocable Trust